Journal article
Authors list: Alidjanov, Jakhongir F.; Fritzenwanker, Moritz; Hoffman, Ivan; Wagenlehner, Florian M.
Publication year: 2017
Pages: 655-670
Journal: Future Microbiology
Volume number: 12
Issue number: 8
ISSN: 1746-0913
eISSN: 1746-0921
DOI Link: https://doi.org/10.2217/fmb-2016-0213
Publisher: Taylor and Francis Group
Abstract:
Ceftazidime-avibactam is a combination of a third-generation cephalosporin and a novel non-beta-lactam beta-lactamase inhibitor. This combination was recently recommended for the treatment of complicated urinary tract infections, including acute pyelonephritis, in adults with limited or no alternative treatment options. The current review is aimed to determine activity, efficacy and safety of ceftazidime-avibactam in the treatment of patients with complicated urinary tract infections.
Citation Styles
Harvard Citation style: Alidjanov, J., Fritzenwanker, M., Hoffman, I. and Wagenlehner, F. (2017) Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections, Future Microbiology, 12(8), pp. 655-670. https://doi.org/10.2217/fmb-2016-0213
APA Citation style: Alidjanov, J., Fritzenwanker, M., Hoffman, I., & Wagenlehner, F. (2017). Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections. Future Microbiology. 12(8), 655-670. https://doi.org/10.2217/fmb-2016-0213
Keywords
antimicrobial agents; avibactam; beta lactamase; beta-lactams; ceftazidime; ceftazidime drug combination; Gram-negative bacteria; INCLUDING ACUTE PYELONEPHRITIS; INHIBITOR COMBINATION; IN-VITRO ACTIVITY; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; NXL104 COMBINATIONS; SPECTRUM BETA-LACTAMASES; Urinary tract infections; US MEDICAL-CENTERS
